Nuvectis Pharma, Inc. - Common Stock - relatórios financeiros (NASDAQ:NVCT) | MetaTrader

Abrir gráfico completo Full chart

Notícias

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

H.C. Wainwright mantém recomendação de compra para ações da Nuvectis Pharma

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

Kaplan compra ações da Nuvectis Pharma (NVCT) no valor de US$ 64.240

Presidente da Nuvectis Pharma, Bentsur, compra ações no valor de US$ 28.600

Diretor da Nuvectis Pharma, Sanchez, compra US$ 75 mil em ações NVCT

H.C. Wainwright mantém recomendação de compra para Nuvectis Pharma com preço-alvo de US$ 10

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900